Search Results - "Qaqish, R.B."

P1351 : An open-label study to evaluate the efficacy and safety of co-formulated ombitasvir/paritaprevir/ritonavir with ribavirin in adults with chronic HCV genotype 4 infection in Egypt by Doss, W, Esmat, G, Qaqish, R.B, Waked, I, Shiha, G, Yosry, A, King, J, Hall, C, Mobashery, N

Get full text

Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with Ribavirin (AGATE-I) by Hassanein, T.I, Asselah, T, Qaqish, R.B, Hezode, C, Mulkay, J.-P, Moreno, C, ElKhashab, M, Alqahtani, S, Yu, Y, Redman, R, Mobashery, N

Get full text

High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (AGATE-I) by Asselah, T, Hezode, C, Qaqish, R.B, ElKhashab, M, Hassanein, T, Papatheodoridis, G, Feld, J, Alqahtani, S, Pilot-Matias, T, Yu, Y, Redman, R, Mobashery, N

Get full text

Ombitasvir/Paritaprevir/Ritonavir with Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egyptian Adults with Chronic HCV Genotype 4 Infection (Agate-II) by Waked, I, Shiha, G, Qaqish, R.B, Esmat, G, Yosry, A, Doss, W, Hassany, M, Soliman, R, Mohey, M.A, Allam, N, Zayed, N, Setze, C.M, Redman, R, Mobashery, N

Get full text

P1345 : A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis by Asselah, T, Hassanein, T, Qaqish, R.B, Feld, J.J, Hezode, C, Zeuzem, S, Ferenci, P, Pilot-Matias, T, Yu, Y, Mobashery, N

Get full text

SAT-277 - Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with Ribavirin (AGATE-I) by Hassanein, T.I., Asselah, T., Qaqish, R.B., Hezode, C., Mulkay, J.-P., Moreno, C., ElKhashab, M., Alqahtani, S., Yu, Y., Redman, R., Mobashery, N.

Get full text

SAT-166 - Ombitasvir/Paritaprevir/Ritonavir with Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egyptian Adults with Chronic HCV Genotype 4 Infection (Agate-II) by Waked, I., Shiha, G., Qaqish, R.B., Esmat, G., Yosry, A., Doss, W., Hassany, M., Soliman, R., Mohey, M.A., Allam, N., Zayed, N., Setze, C.M., Redman, R., Mobashery, N.

Get full text

SAT-278 - High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (AGATE-I) by Asselah, T., Hezode, C., Qaqish, R.B., ElKhashab, M., Hassanein, T., Papatheodoridis, G., Feld, J., Alqahtani, S., Pilot-Matias, T., Yu, Y., Redman, R., Mobashery, N.

Get full text